Drugs / AZD1222
AZD1222
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05007275 | Oct 2021 → Jun 2024 | COVID-19 | Imperial College London | Unknown | No outcome recorded |
| Phase 1 | NCT04816019 | Apr 2021 → Sep 2022 | COVID-19 | University of Oxford | Completed | No outcome recorded |
| Phase 1/24 trials · 1 missed | ||||||
| Phase 1/2 | NCT04684446 | Sep → Nov 2021 | COVID-19 | R-Pharm | Completed | No outcome recorded |
| Phase 1/2 | NCT04760730 | Jul 2021 → Mar 2022 | COVID-19 | R-Pharm | Completed | No outcome recorded |
| Phase 1/2 | NCT04444674 | Jun → Dec 2020 | COVID-19 | University of Oxford | Unknown | Missed primary |
| Phase 1/2 | NCT04324606 | Apr 2020 → Feb 2025 | Coronaviridae infectious disease | University of Oxford | Completed | No outcome recorded |
| Phase 25 trials · 2 met primary | ||||||
| Phase 2 | NCT05197153 | Jan → Jun 2022 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 2 | NCT05054621 | Sep 2021 → Aug 2022 | COVID-19 | Chang Gung Memorial Hospital | Completed | Met primary |
| Phase 2 | NCT05027672 | Jul → Aug 2021 | — | Ministerio de Salud de Ciudad Autónoma de Buenos Aires | Unknown | No outcome recorded |
| Phase 2 | NCT04907331 | May → Nov 2021 | COVID-19 | Medical University Innsbruck | Unknown | Met primary |
| Phase 2 | NCT04686773 | Mar → Oct 2021 | COVID-19 | R-Pharm | Completed | No outcome recorded |
| Phase 2/33 trials · 2 met primary | ||||||
| Phase 2/3 | NCT04973449 | Jun 2021 → Feb 2022 | COVID-19 | AstraZeneca | Completed | Met primary |
| Phase 2/3 | NCT05059106 | Jun 2021 → Jun 2022 | COVID-19 | Federal University of Espirito Santo | Unknown | No outcome recorded |
| Phase 2/3 | NCT04400838 | May 2020 → Feb 2025 | COVID-19 | University of Oxford | Completed | Met primary |
| Phase 35 trials · 2 met primary | ||||||
| Phase 3 | NCT05011526 | Oct → Dec 2021 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 3 | NCT05715944 | Sep 2021 → Dec 2022 | COVID-19 | Botswana Harvard AIDS Institute Partnership | Completed | No outcome recorded |
| Phase 3 | NCT04540393 | Sep → Dec 2020 | COVID-19 | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 3 | NCT04516746 | Aug 2020 → Mar 2021 | COVID-19 | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT04536051 | Jun 2020 → Sep 2021 | COVID-19 | University of Oxford | Unknown | Met primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT05343871 | Jul 2022 → Jul 2023 | COVID-19 | Albert B. Sabin Vaccine Institute | Completed | No outcome recorded |
| Phase 4 | NCT05057897 | Jan 2022 → Apr 2023 | COVID-19 | AstraZeneca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04914832 | Aug 2021 → Sep 2022 | COVID-19, viral pneumonia | Shabir Madhi | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04794946 | Mar 2021 → Mar 2022 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| Comparator or background therapy16 trials | ||||||
| Phase 1/2 | NCT04568031 Comparator | Aug 2020 → Nov 2021 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT05542693 Comparator | Jan → Mar 2023 | COVID-19 | Azidus Brasil | Unknown | No outcome recorded |
| Phase 2 | NCT04988048 Comparator | Aug → Sep 2021 | COVID-19 | Ministry of Public Health, Argentina | Unknown | No outcome recorded |
| Phase 2 | NCT04983537 Comparator | Jul → Sep 2021 | — | Ministerio de Salud de Ciudad Autónoma de Buenos Aires | Unknown | No outcome recorded |
| Phase 2 | NCT04962906 Comparator | Jul → Aug 2021 | — | Ministerio de Salud de Ciudad Autónoma de Buenos Aires | Completed | No outcome recorded |
| Phase 2/3 | NCT05012943 Comparator | Aug 2021 → Jan 2023 | — | Vinbiocare Biotechnology Joint Stock Company | Completed | Met primary |
| Phase 3 | NCT05534035 Comparator | Feb → Apr 2023 | COVID-19 | Everest Medicines (Singapore) Pte. Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05572879 Comparator | Oct 2022 → Jun 2023 | COVID-19 | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05198596 Comparator | Jul → Nov 2022 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 3 | NCT05603052 Comparator | Jul 2022 → Jan 2024 | COVID-19 | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05426343 Comparator | Jul → Oct 2022 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 3 | NCT05188677 Comparator | Jun 2022 → Jun 2023 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 3 | NCT05567471 Comparator | Feb → May 2022 | COVID-19 | Bharat Biotech International Limited | Completed | No outcome recorded |
| Phase 3 | NCT04864561 Comparator | Apr → Jul 2021 | COVID-19 | Valneva Austria GmbH | Completed | Met primary |
| Phase 4 | NCT04775069 Comparator | May 2021 → Sep 2023 | liver disorder | Humanity & Health Medical Group Limited | Completed | No outcome recorded |
| — | NCT05074368 Comparator | Jul 2021 → Apr 2022 | — | National Taiwan University Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 28
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | AstraZeneca | Results ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies astrazeneca.com ↗
Persistently high immunogenicity and between-country differences driven by hybrid immunity from primary-series AZD2816 or AZD1222 (ChAdOx1 nCoV-19) and Omicron infections |
| 2022-11-01 | AstraZeneca | Regulatory Vaxzevria receives full Marketing Authorisation in the EU for the prevention of COVID-19 astrazeneca.com ↗
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted full Marketing Authorisation (MA) in the European Union (EU). |
| 2022-05-23 | AstraZeneca | Regulatory Vaxzevria approved in the EU as third dose booster against COVID-19 astrazeneca.com ↗
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults. |
| 2022-02-13 | R-Pharm | Results Безопасность комбинации вакцин «АстраЗенека» и «Спутник Лайт» подтверждена результатами исследований в России и Азербайджане r-pharm.com ↗
В ходе исследований с участием 100 добровольцев в России и 100 добровольцев в Азербайджане комбинация препаратов продемонстрировала оптимальный профиль безопасности и переносимости, что соотносится с результатами ранее проведенных клинических исследований по безопасности вакцин «АстраЗенека», «Спутник V» и «Спутник Лайт». |
| 2022-01-13 | AstraZeneca | Results New Vaxzevria data further support its use as third dose booster astrazeneca.com ↗
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha and Gamma variants following third dose booster with Vaxzevria |
| 2021-12-23 | AstraZeneca | Results Vaxzevria significantly boosted antibody levels against Omicron astrazeneca.com ↗
AstraZeneca’s Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster, according to data from a new laboratory study. |
| 2021-07-28 | AstraZeneca | Results Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose astrazeneca.com ↗
The data, published in The Lancet today, demonstrated the estimated rate of TTS following a second dose of Vaxzevria was 2.3 per million vaccinees, comparable to the background rate observed in an unvaccinated population. |
| 2021-07-28 | AstraZeneca | Results Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people astrazeneca.com ↗
Safety profiles of Vaxzevria, and the mRNA-based vaccine were similar and overall favourable. |
| 2021-07-23 | AstraZeneca | Results Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern astrazeneca.com ↗
The vaccine also showed a high level of effectiveness against the Delta (B.617.2, ‘Indian’) and Alpha (B.1.1.7, ‘Kent’) variants with an 87% and 90% reduction of hospitalisations or deaths respectively. |
| 2021-06-28 | AstraZeneca | Results Vaxzevria induced immunity for at least one year following a single dose and strong immune responses following either a late second dose or a third dose astrazeneca.com ↗
An extended interval between the first and second dose of Vaxzevria of up to 45 weeks, resulted in up to an 18 fold increase in antibody response, measured 28 days after the second dose. |
| 2021-06-15 | AstraZeneca | Results COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant astrazeneca.com ↗
Real world data from PHE, published as a pre-print , demonstrated two doses of COVID-19 Vaccine AstraZeneca are 92% effective against hospitalisation due to the Delta variant and showed no deaths among those vaccinated. |
| 2021-05-21 | AstraZeneca | Regulatory AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan astrazeneca.com ↗
AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]) , formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2. |
| 2021-03-25 | AstraZeneca | Results AZD1222 US Phase III primary analysis confirms safety and efficacy astrazeneca.com ↗
Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. |
| 2021-03-22 | AstraZeneca | Results AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis astrazeneca.com ↗
The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. |
| 2021-03-18 | AstraZeneca | Regulatory UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective astrazeneca.com ↗
Today the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks. |
| 2021-03-18 | AstraZeneca | Regulatory UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is effective and generally well-tolerated astrazeneca.com ↗
Today the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks. |
| 2021-03-14 | AstraZeneca | Results Update on the safety of COVID-19 Vaccine AstraZeneca astrazeneca.com ↗
There has also been no evidence of increased bleeding in over 60,000 participants enrolled. |
| 2021-02-15 | AstraZeneca | Regulatory AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization astrazeneca.com ↗
AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65. |
| 2021-02-03 | AstraZeneca | Results COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials astrazeneca.com ↗
Results demonstrated vaccine efficacy of 76% (CI: 59% to 86%) after a first dose, with protection maintained to the second dose. |
| 2021-01-29 | AstraZeneca | Regulatory COVID-19 Vaccine AstraZeneca recommended for use in the EU astrazeneca.com ↗
AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. |
| 2021-01-06 | AstraZeneca | Regulatory Serum Institute of India obtains emergency use authorisation in India for AstraZeneca’s COVID-19 vaccine astrazeneca.com ↗
AstraZeneca’s COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunisation of adults. |
| 2020-12-30 | AstraZeneca | Regulatory AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK astrazeneca.com ↗
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of COVID-19 Vaccine AstraZeneca, formerly AZD1222, for the active immunisation of individuals 18 years or older. |
| 2020-12-08 | AstraZeneca | Results AZD1222 Oxford Phase III trials interim analysis results published in The Lancet astrazeneca.com ↗
Results of an interim analysis of the Phase III programme conducted by Oxford University with AZD1222, peer-reviewed and published in The Lancet today, demonstrated that the vaccine is safe and effective at preventing symptomatic COVID-19 and that it protects against severe disease and hospitalisation. |
| 2020-11-23 | AstraZeneca | Results AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 astrazeneca.com ↗
The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. |
| 2020-10-23 | AstraZeneca | Regulatory FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial astrazeneca.com ↗
The Food and Drug Administration (FDA) today authorised the restart in the US, following the resumption of trials in other countries in recent weeks. |
| 2020-10-02 | AstraZeneca | Regulatory COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India astrazeneca.com ↗
The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). |
| 2020-09-12 | AstraZeneca | Regulatory COVID-19 vaccine AZD1222 clinical trials resumed in the UK astrazeneca.com ↗
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so. |
| 2020-07-20 | AstraZeneca | Results COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial astrazeneca.com ↗
Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants. |
All press releases naming this drug 32 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 47 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1222 | “ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein.” PMID 33335323 ↗ Dec 202024“Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks” NCT05059106 ↗ “2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days).” NCT04794946 ↗ “primary series AZD1222 (ChAdOx1 nCoV-19) vaccination in South African adults aged 18-65 years” PMID 37149443 ↗ Apr 2023 “despite widespread use of ChAdOx1 nCoV-19 (AZD1222) as a COVID-2019 booster” PMID 40686533 ↗ Jul 2025 “The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved” PMID 33617777 ↗ Feb 2021 |
| Known as | Astra Zeneca COVID-19 vaccine | “The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6.” NCT05534035 ↗1“Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)” NCT05012943 ↗ |
| Known as | AstraZeneca (ChAdOx1 nCoV-19 vaccine AZD1222) | “AstraZeneca (ChAdOx1 nCoV-19 vaccine AZD1222)” NCT04988048 ↗ |
| Known as | Astrazeneca-Oxford | “The subjects will be vaccinated with adenovirus-vector COVID-19 vaccine (Astrazeneca-Oxford).” NCT04775069 ↗ |
| Known as | ChAdOx1 | “The purpose of this study is to demonstrate the immunogenicity and safety of AZD1222, AstraZeneca's approved ChAdOx1 vector vaccine against SARS-CoV-2, in SARS-CoV-2...” NCT05057897 ↗1“We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca) and/or mRNA (mRNA-1273, Moderna) vaccines.” PMID 35305895 ↗ Mar 2022 |
| Known as | ChAdOx1 nCOV-19 | “BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus...” PMID 34587382 ↗ Sep 202119“This study will attempt to determine whether administration of a heterologous regimen combining a first dose of Gam-COVID-Vac with a second dose of ChAdOx1 nCoV-19 or...” NCT04962906 ↗ “Development of AZD1222, previously referred to as ChAdOx1 nCoV-19, was initiated by the University of Oxford, UK, with subsequent transfer of development activities to AstraZeneca.” NCT04914832 ↗ “ChAdOx1 nCoV-19 vaccine AZD1222 AstraZeneca-Oxford - United Kingdom.” NCT04988048 ↗ “Astra Zeneca's vaccine (ChAdOx1 nCoV-19) as a second dose” NCT05027672 ↗ “phase 1/2 trial of AZD1222 (ChAdOx1 nCoV-19) in Japan” PMID 37271703 ↗ Jun 2023 “AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters” PMID 37783221 ↗ Sep 2023 “Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)” NCT05012943 ↗ “Current/Former names/alias(es):ChAdOx1 nCoV-19” NCT05715944 ↗ “A Study of Intranasal ChAdOx1 nCOV-19” NCT04816019 ↗ |
| Known as | ChAdOx1-S | “Comparison of Heterologous Vaccination With an Vaxzevria (ChAdOx1-S) Prime and a Comirnaty (BNT162b2) Boost to Homolog Vaccination” NCT04907331 ↗1“AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:” NCT05343871 ↗ |
| Known as | Covishield | “Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart” NCT04400838 ↗ |
| Known as | Vaxzevria | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05188677 ↗ |
| Modality | Vaccine | “ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein.” PMID 33335323 ↗ Dec 2020 |
| Route | Intramuscular | “The vaccine will be administered intramuscularly (IM) into the deltoid region of the arm” NCT04324606 ↗ |